DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Vibativ (Telavancin Hydrochloride) - Published Studies

 
 



Vibativ Related Published Studies

Well-designed clinical trials related to Vibativ (Telavancin)

Telavancin versus vancomycin for hospital-acquired pneumonia due to gram-positive pathogens. [2011.01.01]

Telavancin versus vancomycin for hospital-acquired pneumonia due to gram-positive pathogens. [2011]

ATLAS trials: efficacy and safety of telavancin compared with vancomycin for the treatment of skin infections. [2010.12]

Effect of Telavancin on the pharmacokinetics of the cytochrome P450 3A probe substrate midazolam: a randomized, double-blind, crossover study in healthy subjects. [2010.02]

Lack of pharmacokinetic drug interactions following concomitant administration of telavancin with aztreonam or piperacillin/tazobactam in healthy participants. [2009.07]

Telavancin versus vancomycin for the treatment of complicated skin and skin-structure infections associated with surgical procedures. [2009.06]

Multiple-dose pharmacokinetics of intravenous telavancin in healthy male and female subjects. [2008.10]

Telavancin versus vancomycin for the treatment of complicated skin and skin-structure infections caused by gram-positive organisms. [2008.06.01]

Well-designed clinical trials possibly related to Vibativ (Telavancin)

Meta-analysis of randomized controlled trials of vancomycin for the treatment of patients with gram-positive infections: focus on the study design. [2012]

New insights into meticillin-resistant Staphylococcus aureus (MRSA) pathogenesis, treatment and resistance. [2012]

Presence of genes encoding the panton-valentine leukocidin exotoxin is not the primary determinant of outcome in patients with complicated skin and skin structure infections due to methicillin-resistant Staphylococcus aureus: results of a multinational trial. [2009.12]

Other research related to Vibativ (Telavancin)

The ATTAIN trials: efficacy and safety of telavancin compared with vancomycin for the treatment of hospital-acquired and ventilator-associated bacterial pneumonia. [2014]

In vitro activity of dalbavancin and telavancin against staphylococci and streptococci isolated from patients in Canadian hospitals: results of the CANWARD 2007-2009 study. [2011.03]

Pharmacodynamics of telavancin studied in an in vitro pharmacokinetic model of infection. [2011.02]

An interspecies extrapolation of the pharmacokinetics of telavancin, a rapidly bactericidal, concentration-dependent antibiotic. [2011.01]

Telavancin: a lipoglycopeptide antimicrobial for the treatment of complicated skin and skin structure infections caused by gram-positive bacteria in adults. [2010.12]

Successful treatment of vancomycin-intermediate Staphylococcus aureus pacemaker lead infective endocarditis with telavancin. [2010.12]

Comparative efficacies of human simulated exposures of telavancin and vancomycin against methicillin-resistant Staphylococcus aureus with a range of vancomycin MICs in a murine pneumonia model. [2010.12]

Telavancin Activity against gram-positive bacteria isolated from patients with skin and skin-structure infections. [2010.10]

In vitro activity of telavancin against Gram-positive isolates from complicated skin and skin structure infections: results from 2 phase 3 (ATLAS) clinical studies. [2010.10]

Single-dose pharmacokinetics and tolerability of telavancin in elderly men and women. [2010.08]

Mass balance and pharmacokinetics of [14C]telavancin following intravenous administration to healthy male volunteers. [2010.08]

New lipoglycopeptides: a comparative review of dalbavancin, oritavancin and telavancin. [2010.05.07]

Activity of telavancin against heterogeneous vancomycin-intermediate Staphylococcus aureus (hVISA) in vitro and in an in vivo mouse model of bacteraemia. [2010.04]

A comparative review of the lipoglycopeptides: oritavancin, dalbavancin, and telavancin. [2010.01]

Lack of effect of moderate hepatic impairment on the pharmacokinetics of telavancin. [2010.01]

ATLAS trials: efficacy and safety of telavancin compared with vancomycin for the treatment of skin infections. [2010]

Telavancin: a novel lipoglycopeptide. [2009.12.15]

Antibiotics for gram-positive bacterial infections: vancomycin, teicoplanin, quinupristin/dalfopristin, oxazolidinones, daptomycin, dalbavancin, and telavancin. [2009.12]

Comparative efficacies of telavancin and vancomycin in preventing device-associated colonization and infection by Staphylococcus aureus in rabbits. [2009.06]

Telavancin: a novel lipoglycopeptide antibiotic. [2009.05]

The role of telavancin in the treatment of MRSA infections in hospital. [2009.04]

Efficacy of telavancin against glycopeptide-intermediate Staphylococcus aureus in the neutropenic mouse bacteraemia model. [2009.04]

Telavancin: a new lipoglycopeptide for gram-positive infections. [2009.03]

Efficacy of telavancin in the treatment of methicillin-resistant Staphylococcus aureus osteomyelitis: studies with a rabbit model. [2009.02]

Ferric carboxymaltose: a review of its use in iron-deficiency anaemia. [2009]

Cost-effectiveness of telavancin versus vancomycin for treatment of complicated skin and skin structure infections. [2008.12]

Telavancin and vancomycin pharmacodynamics with Staphylococcus aureus in an in vitro dynamic model. [2008.11]

A new lipoglycopeptide: telavancin. [2008.08]

Comparative surveillance study of telavancin activity against recently collected gram-positive clinical isolates from across the United States. [2008.07]

Telavancin penetration into human epithelial lining fluid determined by population pharmacokinetic modeling and Monte Carlo simulation. [2008.07]

Telavancin: an antimicrobial with a multifunctional mechanism of action for the treatment of serious gram-positive infections. [2008.04]

A review of telavancin in the treatment of complicated skin and skin structure infections (cSSSI). [2008.02]

Dalbavancin and telavancin: novel lipoglycopeptides for the treatment of Gram-positive infections. [2008.02]

Other possibly related research studies

Treatment of infections caused by antimicrobial-resistant gram-positive bacteria. [2010.09]

Antimicrobial treatment of nosocomial meticillin-resistant Staphylococcus aureus (MRSA) pneumonia: current and future options. [2010.08.17]

Comparative effectiveness of antibiotics for the treatment of MRSA complicated skin and soft tissue infections. [2010.07]

New antimicrobial agents for methicillin-resistant Staphylococcus aureus. [2009.12]

Future treatment options for Gram-positive infections--looking ahead. [2009.12]

[Update on antimicrobial chemotherapy] [2010.03]

Treatments for skin and soft-tissue and surgical site infections due to MDR Gram-positive bacteria. [2009.09]

Microbiology of drugs for treating multiply drug-resistant Gram-positive bacteria. [2009.09]

Has the era of untreatable infections arrived? [2009.09]

Antimicrobial development in the era of emerging resistance. [2009.07]

New treatments for methicillin-resistant Staphylococcus aureus. [2009.10]

Forthcoming therapeutic perspectives for infections due to multidrug-resistant Gram-positive pathogens. [2009.03]

[Consensus document for the treatment of bacteremia and endocarditis caused by methicillin-resistent Staphylococcus aureus. Sociedad Espanola de Enfermedades Infecciosas y Microbiologia Clinica] [2009.02]

New antibiotics for healthcare-associated pneumonia. [2009.02]

Vancomycin resistance: are there better glycopeptides coming? [2008.12]

[New antimicrobials against Gram-positive organisms] [2008]

Emergence and management of drug-resistant enterococcal infections. [2008.10]

Investigational antimicrobial drugs for bloodstream infections. [2008.08]

An overview of harms associated with beta-lactam antimicrobials: where do the carbapenems fit in? [2008]

Pharmacologic options for CNS infections caused by resistant Gram-positive organisms. [2008.02]

Registered and investigational drugs for the treatment of methicillin-resistant Staphylococcus aureus infection. [2008.01]

Genotypic characteristics of Staphylococcus aureus isolates from a multinational trial of complicated skin and skin structure infections. [2008.02]

Update on prevalence and treatment of methicillin-resistant Staphylococcus aureus infections. [2007.12]

Treatment of infections caused by resistant Staphylococcus aureus. [2007]

Current medical management of diabetic foot infections. [2010.11]

Antimicrobial treatment of nosocomial meticillin-resistant Staphylococcus aureus (MRSA) pneumonia: current and future options. [2010.11]

Outpatient parenteral antimicrobial therapy: Recent developments and future prospects. [2010.08]

Antimicrobial treatment of nosocomial meticillin-resistant Staphylococcus aureus (MRSA) pneumonia: current and future options. [2010]

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017